Pedro Henrique Silva Gomes-Ferreira1, Roberta Okamoto2, Sabrina Ferreira1, Danila De Oliveira2, Gustavo Antonio Correa Momesso3, Leonardo Perez Faverani1. 1. Department of Surgery and Integrated Clinic, Araçatuba Dental School, Univ. Estadual Paulista (UNESP), Araçatuba, São Paulo, Brazil. 2. Department of Basic Sciences, Araçatuba Dental School, Productivity scholarship (CNPQ), Univ. Estadual Paulista (UNESP), Araçatuba, São Paulo, Brazil. 3. Department of Surgery and Integrated Clinic, Araçatuba Dental School, Univ. Estadual Paulista (UNESP), Araçatuba, São Paulo, Brazil. gustavomomesso@gmail.com.
Abstract
PURPOSE: This study aimed to identify the main indications for the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for bone repair and maintenance in the maxilla and mandible through a review of clinical trials evaluating the viability of using rhBMP-2 to delay the installation of dental implants, thus allowing satisfactory bone formation and long-term osseointegration. METHODS: Literature search of the PubMed/Medline databases was performed using the following MeSH index terms-"bone morphogenetic protein 2" and "dentistry". Only clinical trials necessarily published in English, related to dentistry, and focused on bone reconstruction in critical defects, post-extraction alveoli, increasing the atrophic alveolar ridge, or surgery for maxillary sinus elevation were included, regardless of the age, sex, ethnicity, associated morbidities, or period of publication. RESULTS: Of the 17 studies identified based on the search filters, 2 were excluded. Therefore, 15 studies were finally included in this review. CONCLUSIONS: Based on the results of our review, we concluded that the use of rhBMP-2 for the preservation of the alveolar ridge after tooth extraction or for increasing the local defects is safe and viable. The use of rhBMP-2/Bio-Oss® for the elevation of the maxillary sinus membrane is unnecessary; however, it can improve and accelerate the maturation process in cases of guided bone regeneration in peri-implant defects. Compounds comprising rhBMP-2, allogenic bone, and plasma-rich platelet (PRP) can act as autograft substitutes in mandibular critical defects.
PURPOSE: This study aimed to identify the main indications for the use of recombinant humanbone morphogenetic protein-2 (rhBMP-2) for bone repair and maintenance in the maxilla and mandible through a review of clinical trials evaluating the viability of using rhBMP-2 to delay the installation of dental implants, thus allowing satisfactory bone formation and long-term osseointegration. METHODS: Literature search of the PubMed/Medline databases was performed using the following MeSH index terms-"bone morphogenetic protein 2" and "dentistry". Only clinical trials necessarily published in English, related to dentistry, and focused on bone reconstruction in critical defects, post-extraction alveoli, increasing the atrophic alveolar ridge, or surgery for maxillary sinus elevation were included, regardless of the age, sex, ethnicity, associated morbidities, or period of publication. RESULTS: Of the 17 studies identified based on the search filters, 2 were excluded. Therefore, 15 studies were finally included in this review. CONCLUSIONS: Based on the results of our review, we concluded that the use of rhBMP-2 for the preservation of the alveolar ridge after tooth extraction or for increasing the local defects is safe and viable. The use of rhBMP-2/Bio-Oss® for the elevation of the maxillary sinus membrane is unnecessary; however, it can improve and accelerate the maturation process in cases of guided bone regeneration in peri-implant defects. Compounds comprising rhBMP-2, allogenic bone, and plasma-rich platelet (PRP) can act as autograft substitutes in mandibular critical defects.
Entities:
Keywords:
Atrophy; Biocompatible materials; Bone morphogenetic protein 2; Bone regeneration
Authors: Robert E Marx; Lawrence Armentano; Alberto Olavarria; Juan Samaniego Journal: Int J Oral Maxillofac Implants Date: 2013 Sep-Oct Impact factor: 2.804
Authors: Eric D Jensen; Lan Pham; Charles J Billington; Kelly Espe; Ann E Carlson; Jennifer J Westendorf; Anna Petryk; Rajaram Gopalakrishnan; Kim Mansky Journal: J Cell Biochem Date: 2010-03-01 Impact factor: 4.429
Authors: L Canullo; M Del Fabbro; S Khijmatgar; S Panda; A Ravidà; G Tommasato; A Sculean; P Pesce Journal: Clin Oral Investig Date: 2021-11-26 Impact factor: 3.606
Authors: Pedro Henrique Silva Gomes Ferreira; Danila De Oliveira; Ciro Borges Duailibe De Deus; Roberta Okamoto Journal: Ann Maxillofac Surg Date: 2018 Jul-Dec
Authors: Su A Park; Hyo-Jung Lee; Sung-Yeol Kim; Keun-Suh Kim; Deuk-Won Jo; Shin-Young Park Journal: J Biomed Mater Res A Date: 2020-08-22 Impact factor: 4.396